Literature DB >> 165242

Treatment of varicella-zoster virus infections with adenine arabinoside.

M T Johnson, R A Buchanan, J P Luby, D Mikulec.   

Abstract

Twenty-three patients with complicated varicella-zoster virus infections were treated with adenine arabinoside. Of 14 patients with herpes zoster, 13 had malignancy treated with irradiation and cytotoxic agents or steroids. Although the duration of active vesicle formation in these patients ranged from two to 14 days before therapy, no new lesions appeared after the fourth day of treatment with adenine arabinoside. Zoster encephalitis developed in one patient on the third day of treatment, and severe postherpetic neuralgia was seen in three patients. Of nine treated patients with primary varicella, six improved, including five with evidence of varicella pneumonia. Two of the three patients with varicella who died were immunosuppressed and had progressive viral pneumonia with persistently high titers of virus in vesicular fluid; the third pateint was a child with Reye's syndrome. Double-blind controlled studies will be necessary to demonstrate the efficacy of adenine arabinoside in the treatment of infections with varicella-zoster virus.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165242     DOI: 10.1093/infdis/131.3.225

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Chemotherapy for varicella-zoster infections.

Authors:  P A Walden; E S Newlands; J C Coleman; M H Tattersall; K D Bagshawe
Journal:  Br Med J       Date:  1977-02-05

2.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

3.  Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis.

Authors:  E L Goodman; J P Luby; M T Johnson
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

4.  In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside.

Authors:  Y J Bryson; J D Connor
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

5.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

6.  In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E De Clercq; J Descamps; M Ogata; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

Review 7.  A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.

Authors:  Sara M Thomasy; David J Maggs
Journal:  Vet Ophthalmol       Date:  2016-04-19       Impact factor: 1.644

8.  Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine.

Authors:  M J Dobersen; M Jerkofsky; S Greer
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

Review 9.  Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.

Authors:  R Whitley; C Alford; F Hess; R Buchanan
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

10.  Chemotherapy of genital herpes simplex virus type 2 infections of female hamsters.

Authors:  H E Renis
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.